CHIP in Health and Disease

Cardiovascular Disease, Clonal Cytopenia of Undetermined Significance (CCUS), Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Myelodysplastic Syndrome, Myocardial Infarction (MI), ST-elevation Myocardial Infarction (STEMI)

Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Somatic Mutations, DNMT3A, TET2, ASXL1, Inflammation, Myeloid Cells, Cardiovascular Disease, Atherosclerosis, Myocardial Infarction, STEMI, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndromes (MDS), Single-Cell RNA Sequencing, Multi-Omics, Immune Profiling, NLRP3 Inflammasome, cGAS-STING Pathway, Precision Medicine, Cardiovascular Risk, Healthy Aging, Chronic Inflammation, Biomarkers

Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling. This observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.

Background and Rationale: Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), arises from acquired somatic mutations in hematopoietic stem and progenitor cells that accumulate throughout life and drive clonal expansion. The most frequently affected genes include DNMT3A, TET2, and ASXL1. While such mutations are also involved in the pathogenesis of hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), progression to overt hematologic cancer occurs only in a minority of affected individuals. In contrast, epidemiological studies have consistently demonstrated a strong association between clonal hematopoiesis and cardiovascular disease. Individuals carrying CHIP-associated mutations have a substantially increased risk of coronary artery disease, myocardial infarction, stroke, and cardiovascular mortality. The magnitude of risk conferred by CHIP has been reported to be comparable to established cardiovascular risk factors such as smoking or hypertension. Experimental and mechanistic studies suggest that CH-associated mutations remodel immune-cell function through epigenetic reprogramming and activation of inflammatory pathways, including the NLRP3 inflammasome and cGAS-STING signaling. These alterations enhance the proliferation, activation, and inflammatory potential of myeloid immune cells, resulting in chronic sterile inflammation that can promote atherosclerosis, vascular injury, and adverse cardiac remodeling. Importantly, clonal hematopoiesis is not considered a disease entity itself but rather a common biological state and independent risk factor for a range of age-related disorders. Since clonal hematopoiesis develops in varying degrees in a substantial proportion of the aging population, understanding its biological consequences represents a major opportunity for disease prevention. Additional support for a causal role of inflammation comes from retrospective analyses of the CANTOS trial, which suggested that individuals carrying somatic TET2 mutations derived particularly strong benefit from anti-inflammatory treatment targeting interleukin-1β. These findings highlight the potential for precision prevention and targeted therapeutic interventions in CH-associated disease. However, a more comprehensive understanding of the cellular and molecular mechanisms linking clonal hematopoiesis to disease development is required for improved risk stratification and the development of novel therapeutic approaches. Study Objectives: The primary objective of this study is to define the inflammatory and immunological landscape across the biological continuum of clonal hematopoiesis, from healthy individuals without detectable CH to individuals with high-risk CH and patients with CH-associated hematologic or cardiovascular disease. Specific objectives include: * High-resolution characterization of immune-cell composition and activation states across different stages of clonal hematopoiesis. * Identification of mutation-associated transcriptional, proteomic, and functional alterations, particularly within the myeloid compartment. * Determination of shared and disease-specific inflammatory pathways associated with progression from CH to clinical hematologic or cardiovascular outcomes. * Generation of mechanistic hypotheses and therapeutic targets for future anti-clonal and anti-inflammatory interventions. Study Design: This is a prospective observational translational research study. A total of six participant groups will be recruited, with approximately 20 participants per group (total n ≈ 120). The groups will represent different stages along the spectrum of clonal hematopoiesis and disease manifestation, including: 1. Healthy individuals without detectable CH or with low-risk molecular profiles. 2. Individuals with high-risk clonal hematopoiesis based on established molecular risk characteristics. 3. Patients with clonal cytopenia of undetermined significance (CCUS). 4. Patients with lower-risk myelodysplastic syndromes (MDS). 5. Patients with ST-segment elevation myocardial infarction (STEMI). 6. An additional comparator group representing the defined CH-risk spectrum according to study-specific inclusion criteria. Study Procedures: Participants will provide peripheral whole-blood samples for comprehensive molecular, cellular, and functional analyses. Planned investigations include: * UMI-based targeted DNA sequencing for detection and quantification of somatic variants in genes associated with clonal hematopoiesis. * Single-cell RNA sequencing (scRNA-seq) of freshly collected whole blood combined with single-cell genotyping approaches (Genotyping of Transcriptomes) to link somatic mutations with cellular phenotypes. * Functional ex vivo immune stimulation assays using freshly collected blood samples. * Proteomic profiling under baseline and stimulated conditions. * Flow cytometric characterization of immune-cell composition and activation states. * Isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs) for downstream validation studies. * Storage of plasma specimens for future analyses, including multiplex cytokine profiling, proteomics, metabolomics, lipidomics, and isolation of extracellular vesicles from platelet-poor plasma. Expected Impact: The study is designed to establish a comprehensive map of inflammatory and immune mechanisms associated with clonal hematopoiesis across its natural history. By defining the biological pathways that connect somatic mutations to hematologic and cardiovascular disease, the project aims to support the development of improved risk stratification tools and enable future preventive, anti-clonal, and anti-inflammatory therapeutic strategies. Ultimately, these efforts may contribute to preventing or delaying progression from healthy aging through clonal hematopoiesis to clinically manifest hematologic and cardiovascular disease.

No related papers found yet.

None listed

Austria